Showing results (211-220 of 723) with videos related to
Sort By:
Pageof 73
BJU International|September 13, 2005
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapyNancy B Davis, Christopher W Ryan, Walter M Stadler, et al.Applied and Environmental Microbiology|April 2, 1999
Degradation of ciprofloxacin by basidiomycetes and identification of metabolites generated by the brown rot fungus Gloeophyllum striatumH G Wetzstein, M Stadler, H V Tichy, et al.International Archives of Allergy and Immunology|May 1, 1995
Cloning of human anti-IgE autoantibodies and their role in the regulation of IgE synthesisB M Stadler, M R Stämpfli, S Miescher, et al.Journal of the National Cancer Institute|September 27, 2007
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancerTheodore G Karrison, Michael L Maitland, Walter M Stadler, et al.Journal of Molecular Biology|August 18, 2009
DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockageAlexander Eggel, Michael J Baumann, Patrick Amstutz, et al.Laryngo- Rhino- Otologie|May 1, 1990
[The clinical significance of anti-IgE antibodies in the treatment of allergic rhinopathy]D Loidolt, C C Vassella, A L de Weck, et al.Immunology Letters|August 3, 2010
DARPins against a functional IgE epitopeMichael J Baumann, Alexander Eggel, Patrick Amstutz, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1982
Monoclonal antibody against human interleukin 2 (IL 2). I. Purification of IL 2 for the production of monoclonal antibodiesB M Stadler, E H Berenstein, R P Siraganian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancerW M Stadler, T Kuzel, B Roth, et al.Anti-Cancer Drugs|June 19, 2004
Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cellsJonathan C Berger, Donald Vander Griend, Walter M Stadler, et al.Pageof 73